← Eichor
Study identifier: NCT07150663 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Nanocrystalline Megestrol Acetate in Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer

Condition: Non-small Cell Lung Cancer  ·  Sponsor: Changchun GeneScience Pharmaceutical Co., Ltd.

PhasePhase 3
Planned participants134
Who can joinAll sexes, 18 Years to 85 Years
Healthy volunteersNo

About this study

This study is a prospective, randomized, parallel-controlled clinical trial, primarily aimed at evaluating the efficacy and safety of Nanocrystalline Megestrol Acetate combined with standard therapy, compared with placebo combined with standard therapy, in improving appetite and body weight during concurrent chemoradiotherapy for patients with locally advanced non-small cell lung cancer.

This description comes directly from the study's public registry record.

Talk to the study team

qian Chu  ·  13212760751  ·  qianchu@tjh.tjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Tongji Hospital, TongjiMedical College, Huazhong University of Science and TechnologyWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07150663